Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $6 | $5 | $3 | $0 |
| Gross Profit | -$6 | -$5 | -$3 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $335 | $280 | $162 | $103 |
| G&A Expenses | $113 | $88 | $58 | $46 |
| SG&A Expenses | $113 | $88 | $58 | $46 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $7 | -$5 | $0 |
| Operating Expenses | $466 | $368 | $220 | $149 |
| Operating Income | -$447 | -$368 | -$220 | -$149 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15 | $16 | -$5 | -$3 |
| Pre-Tax Income | -$432 | -$351 | -$225 | -$152 |
| Tax Expense | $1 | $0 | -$3 | -$0 |
| Net Income | -$433 | -$352 | -$222 | -$152 |
| % Margin | – | – | – | – |
| EPS | -2.67 | -2.32 | -1.63 | -1.29 |
| % Growth | -15.1% | -42.3% | -26.4% | – |
| EPS Diluted | -2.67 | -2.32 | -1.63 | -1.29 |
| Weighted Avg Shares Out | 162 | 151 | 137 | 118 |
| Weighted Avg Shares Out Dil | 162 | 151 | 137 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $10 | $0 | $0 |
| Interest Expense | $11 | $10 | $0 | $0 |
| Depreciation & Amortization | $6 | $5 | $3 | $0 |
| EBITDA | -$416 | -$337 | -$212 | -$149 |
| % Margin | – | – | – | – |